Lakewood-Amedex Biotherapeutics, Inc. (LABT)
0.2373
-0.05
(-16.74%)
USD |
NASDAQ |
Oct 29, 16:00
0.219
-0.02
(-7.71%)
After-Hours: 04:27
Lakewood-Amedex Biotherapeutics Enterprise Value : -3.968M for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | -3.968M |
| October 28, 2026 | -3.865M |
| October 27, 2026 | -3.862M |
| October 26, 2026 | -3.869M |
| October 23, 2026 | -3.811M |
| October 22, 2026 | -3.421M |
| October 21, 2026 | -3.472M |
| October 20, 2026 | -3.230M |
| October 19, 2026 | -3.218M |
| October 16, 2026 | -3.225M |
| October 15, 2026 | -3.155M |
| October 14, 2026 | -3.113M |
| October 13, 2026 | -2.978M |
| October 12, 2026 | -2.898M |
| October 09, 2026 | -2.786M |
| October 08, 2026 | -2.765M |
| October 07, 2026 | -2.640M |
| October 06, 2026 | -2.602M |
| October 05, 2026 | -2.629M |
| October 02, 2026 | -2.460M |
| October 01, 2026 | -2.466M |
| September 30, 2026 | -2.411M |
| September 29, 2026 | -2.336M |
| September 28, 2026 | -1.989M |
| September 25, 2026 | -0.8606M |
| Date | Value |
|---|---|
| September 24, 2026 | -0.5244M |
| September 23, 2026 | -0.622M |
| September 22, 2026 | -0.1665M |
| September 21, 2026 | -0.0363M |
| September 18, 2026 | -0.1665M |
| September 17, 2026 | -0.4485M |
| September 16, 2026 | 0.0504M |
| September 15, 2026 | 0.224M |
| September 14, 2026 | 0.1155M |
| September 11, 2026 | 0.3324M |
| September 10, 2026 | -0.0363M |
| September 09, 2026 | 0.5493M |
| September 08, 2026 | 0.2457M |
| September 04, 2026 | -0.4051M |
| September 03, 2026 | -0.3617M |
| September 02, 2026 | 0.007M |
| September 01, 2026 | 1.504M |
| August 31, 2026 | 0.9398M |
| August 28, 2026 | 0.506M |
| August 27, 2026 | 0.9181M |
| August 26, 2026 | 0.8313M |
| August 25, 2026 | 0.4843M |
| August 24, 2026 | 0.1372M |
| August 21, 2026 | 0.3758M |
| August 20, 2026 | 0.2673M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.312B |
| Oncolytics Biotech, Inc. | 49.64M |
| Sangamo Therapeutics, Inc. | 41.42M |
| Sarepta Therapeutics, Inc. | 2.288B |
| Anixa Biosciences, Inc. | 99.17M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.772M |
| Total Expenses (Quarterly) | 3.772M |
| EPS Diluted (Quarterly) | -1.739 |
| Earnings Yield | -4.36K% |